As of November 26, 2019, apomorphine hydrochloride, sold under the brand name Movapo, has been made available as a part of BC PharmaCare’s Limited Drug Coverage Program under Special Authority.
Special Authority grants coverage to a drug, medical supply, or medical device that otherwise would not be eligible for full coverage. Coverage is provided for patients with specific medical circumstances.
Limited coverage drugs are not generally considered to be first-line therapies or there are more cost-effective alternatives.
To be eligible for coverage of these drugs, the patient must meet criteria pre-defined by PharmaCare.
For more information visit: http://bit.ly/Movapo-Announcement
